6 assets in Laryngeal Carcinoma

Therapeutic assets addressing Laryngeal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Laryngeal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Laryngeal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Laryngeal Carcinoma	VM Oncology, LLC	P1/2	CCC (48)
Docetaxel Laryngeal Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Pembrolizumab Laryngeal Carcinoma	VM Oncology, LLC	P1/2	CCC (48)
SX682 Laryngeal Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)